

CITATION REPORT

List of articles citing

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE

DOI: 10.1016/j.opthta.2013.02.034
Ophthalmology, 2013, 120, 2013-22.

Source: <https://exaly.com/paper-pdf/55598592/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|-----|-----------|
| 673 | Characterizing relationship between optical microangiography signals and capillary flow using microfluidic channels. 2016 , 7, 2709 | | |
| 672 | Characterizing relationship between optical microangiography signals and capillary flow using microfluidic channels. 2016 , 7, 2709 | | |
| 671 | Characterizing relationship between optical microangiography signals and capillary flow using microfluidic channels. 2016 , 7, 2709 | | |
| 670 | Diabetic retinopathy: current concepts and emerging therapy. 2013 , 42, 721-45 | | 13 |
| 669 | Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema. 2014 , 231, 16-22 | | 11 |
| 668 | [VEGF inhibitors in vitreoretinal interventions]. 2013 , 110, 926-34 | | |
| 667 | Inflammation and pharmacological treatment in diabetic retinopathy. 2013 , 2013, 213130 | | 58 |
| 666 | Anti-vascular endothelial growth factor therapy for diabetic macular edema. 2013 , 4, 151-69 | | 111 |
| 665 | Evolving strategies in the management of diabetic retinopathy. 2013 , 20, 273-82 | | 18 |
| 664 | Ranibizumab. 2013 , 30, 392-393a | | |
| 663 | Diabetes-induced superoxide anion and breakdown of the blood-retinal barrier: role of the VEGF/uPAR pathway. 2013 , 8, e71868 | | 19 |
| 662 | Biomarkers in diabetic retinopathy and the therapeutic implications. 2013 , 2013, 193604 | | 31 |
| 661 | Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis. 2014 , 9, e102309 | | 44 |
| 660 | Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials. 2014 , 9, e115797 | | 15 |
| 659 | Sustained-release corticosteroid options. 2014 , 2014, 164692 | | 37 |
| 658 | Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema. 2014 , 3, 5 | | 49 |
| 657 | A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2014 , 45, 521-4 | 1.4 | 20 |

| | | | |
|-----|--|-----|-----|
| 656 | Current concepts in diabetic retinopathy. 2014 , 38, 416-25 | | 32 |
| 655 | Ranibizumab for the treatment of degenerative ocular conditions. <i>Clinical Ophthalmology</i> , 2014 , 8, 1187-98 | | 10 |
| 654 | Treatment decisions in diabetic macular edema based on optical coherence tomography retinal thickness map: LET classification. 2014 , 252, 1687-8 | | 7 |
| 653 | What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?. <i>British Journal of Ophthalmology</i> , 2014 , 98 Suppl 1, i7-10 | 5.5 | 47 |
| 652 | Intravitreal injections: a review of the evidence for best practice: response. 2014 , 42, 98-100 | | 1 |
| 651 | Emergency department visits after intravitreal bevacizumab and ranibizumab injections in diabetic patients. 2014 , 49, e146-8 | | |
| 650 | Vitrectomy for Diabetic Macular Edema. 2014 , 2, 167-174 | | 3 |
| 649 | Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy. 2014 , 2, 175-183 | | |
| 648 | No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. <i>Retina</i> , 2014 , 34, 951-7 | 3.6 | 47 |
| 647 | Bevacizumab and diabetic vitrectomy. 2014 , 54, 111-26 | | 1 |
| 646 | Intravitreal injection technique and monitoring: updated guidelines of an expert panel. <i>Retina</i> , 2014 , 34 Suppl 12, S1-S18 | 3.6 | 163 |
| 645 | Anti-VEGF for the management of diabetic macular edema. 2014 , 2014, 632307 | | 39 |
| 644 | Pharmacological approach to diabetic macular edema. 2014 , 51, 88-95 | | 18 |
| 643 | Advances in diabetic retinopathy. 2014 , 18, 772-7 | | 7 |
| 642 | Diabetic macular edema: changing treatment paradigms. 2014 , 25, 502-7 | | 18 |
| 641 | Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. <i>Ophthalmology</i> , 2014 , 121, 1783-9 | 7.3 | 130 |
| 640 | Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. 2014 , 25, 23-33 | | 273 |
| 639 | Refining the treatment parameters of diabetic retinopathy: new prospects and limitations on the horizon. 2014 , 28, 119 | | 0 |

| | | | |
|-----|--|-----|-----|
| 638 | Phenotypes and biomarkers of diabetic retinopathy. 2014 , 41, 90-111 | | 93 |
| 637 | A review of anti-VEGF agents for proliferative diabetic retinopathy. <i>Eye</i> , 2014 , 28, 510-20 | 4-4 | 153 |
| 636 | Anti-vascular endothelial growth factor for diabetic macular oedema. 2014 , CD007419 | | 94 |
| 635 | Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. <i>Ophthalmology</i> , 2014 , 121, 1892-903 | 7-3 | 109 |
| 634 | Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications. 2014 , 29, 257-62 | | 21 |
| 633 | Complications of intravitreal injections in patients with diabetes. 2014 , 29, 276-89 | | 32 |
| 632 | A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. <i>Ophthalmology</i> , 2014 , 121, 2473-81 | 7-3 | 210 |
| 631 | Effects of fenofibric acid on diabetic macular edema: the MacuFen study. 2014 , 21, 307-17 | | 18 |
| 630 | Anti-VEGF therapy for diabetic macular edema. 2014 , 14, 510 | | 49 |
| 629 | Genetics of diabetic retinopathy. 2014 , 14, 515 | | 46 |
| 628 | Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data. 2014 , 30, 729-51 | | 15 |
| 627 | Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. 2014 , 37, 900-5 | | 83 |
| 626 | Radial versus raster spectral-domain optical coherence tomography scan patterns for detection of macular pathology. <i>American Journal of Ophthalmology</i> , 2014 , 158, 345-353.e2 | 4-9 | 15 |
| 625 | Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. <i>Ophthalmology</i> , 2014 , 121, 1904-14 | 7-3 | 693 |
| 624 | Neurodegeneration in diabetic retinopathy: Current concepts and therapeutic implications. 2014 , 30, 72-79 | | 0 |
| 623 | [Physician information sheet: Treatment of diabetic macular edema]. 2015 , 38, e191-7 | | 1 |
| 622 | Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy. 2015 , 90, 475-480 | | |
| 621 | Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. 2015 , 15, 150 | | 40 |

| | | | |
|-----|--|-----|-----|
| 620 | Diabetic Retinopathy and Diabetic Macular Edema. 2016 , 55, 137-46 | | 51 |
| 619 | Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials. <i>Ophthalmology</i> , 2015 , 122, 2504-13.e1 | 7.3 | 100 |
| 618 | Chapter 10: Diabetic Macular Edema. 2015 , 82-91 | | |
| 617 | Diabetes und Auge. 2015 , 11, 292-299 | | |
| 616 | Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions. 2015 , 98, 522-33 | | 29 |
| 615 | VITRECTOMY WITH INTERNAL LIMITING MEMBRANE PEELING FOR TRACTIONAL AND NONTRACTIONAL DIABETIC MACULAR EDEMA: Long-term Results of a Comparative Study. <i>Retina</i> , 2015 , 35, 921-8 | 3.6 | 29 |
| 614 | EVOLUTION OF CONTROLLING DIABETIC RETINOPATHY: Changing Trends in the Management of Diabetic Macular Edema at a Single Institution Over the Past Decade. <i>Retina</i> , 2015 , 35, 929-34 | 3.6 | 16 |
| 613 | INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA. <i>Retina</i> , 2015 , 35, 1429-35 | 3.6 | 34 |
| 612 | Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective. 2015 , 7, 235-47 | | 19 |
| 611 | The clinical utility of aflibercept for diabetic macular edema. 2015 , 8, 473-82 | | 6 |
| 610 | New Therapeutic Approaches in Diabetic Retinopathy. 2015 , 12, 196-210 | | 23 |
| 609 | Sterile Inflammation after Intravitreal Injection of Aflibercept in a Korean Population. 2015 , 29, 325-30 | | 16 |
| 608 | Pharmakologische Ansätze zur Behandlung des diabetischen Makulaödems. 2015 , 1, 8-15 | | |
| 607 | 22 anti-vascular endothelial growth factor (anti-VEGF) therapy Optical Coherence Tomography and Anti-Vascular Endothelial Growth Factor Therapy. 2015 , | | |
| 606 | Current perspectives on ranibizumab. <i>Clinical Ophthalmology</i> , 2015 , 9, 533-42 | 2.5 | 14 |
| 605 | A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. <i>Clinical Ophthalmology</i> , 2015 , 9, 801-11 | 2.5 | 43 |
| 604 | Morphology and Function over a One-Year Follow Up Period after Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema. 2015 , 10, e0145663 | | 29 |
| 603 | Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials. <i>Ophthalmology</i> , 2015 , 122, 1573-9 | 7.3 | 42 |

| | | | |
|-----|---|-----|----|
| 602 | Biomarkers of Cardiometabolic Risk, Inflammation and Disease. 2015 , | | 2 |
| 601 | Prognosis of patients with diabetic macular edema before Japanese approval of anti-vascular endothelial growth factor. 2015 , 59, 244-51 | | 2 |
| 600 | Prevalence and determinants of undiagnosed diabetic retinopathy and vision-threatening retinopathy in a multiethnic Asian cohort: the Singapore Epidemiology of Eye Diseases (SEED) study. <i>British Journal of Ophthalmology</i> , 2015 , 99, 1614-21 | 5.5 | 52 |
| 599 | Functional outcome of macular edema in different retinal disorders. 2015 , 48, 119-36 | | 22 |
| 598 | Monitoring VEGF levels with low-volume sampling in major vision-threatening diseases: age-related macular degeneration and diabetic retinopathy. 2015 , 15, 2357-63 | | 19 |
| 597 | Screening for diabetic retinopathy: the optometrist's perspective. 2015 , 1 | | 4 |
| 596 | Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema. <i>Diabetes</i> , 2015 , 64, 3588-99 | 0.9 | 49 |
| 595 | INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS. <i>Retina</i> , 2015 , 35, 2440-9 | 3.6 | 66 |
| 594 | Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). 2015 , 15, 52 | | 22 |
| 593 | Nonbiological pharmacotherapies for the treatment of diabetic macular edema. 2015 , 16, 2625-35 | | 2 |
| 592 | [Diabetic maculopathy]. 2015 , 112, 871-83; quiz 884-6 | | 3 |
| 591 | Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. 2015 , 6, 44-50 | | 22 |
| 590 | A platform of integrative studies from in vitro to in vivo experiments: towards drug development for ischemic retinopathy. 2015 , 69, 367-73 | | 4 |
| 589 | RaScaL: A Pilot Study to Assess the Efficacy, Durability, and Safety of a Single Intervention with Ranibizumab plus Peripheral Laser for Diabetic Macular Edema Associated with Peripheral Nonperfusion on Ultrawide-Field Fluorescein Angiography. 2014 , | | 7 |
| 588 | [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema]. 2015 , 38, 159-67 | | 4 |
| 587 | Automated retinal image analysis for diabetic retinopathy in telemedicine. 2015 , 15, 14 | | 43 |
| 586 | Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. <i>Ophthalmology</i> , 2015 , 122, 779-86 | 7.3 | 54 |
| 585 | Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant. <i>Ophthalmology and Therapy</i> , 2015 , 4, 51-8 | 5 | 14 |

| | | | |
|-----|---|-----|-----|
| 584 | Dexamethasone Implants in Patients with Non- or Refractory Diffuse Diabetic Macular Edema. 2015 , 233, 176-85 | | 57 |
| 583 | Nanoparticles for the treatment of ocular neovascularizations. 2015 , 95, 294-306 | | 27 |
| 582 | Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). <i>Eye</i> , 2015 , 29, 534-41 | 4.4 | 27 |
| 581 | Targeting the Effect of VEGF in Diabetic Macular Edema. 2015 , 373, 481-2 | | 5 |
| 580 | Diabetic Macular Edema: Options for Adjunct Therapy. 2015 , 75, 1461-9 | | 16 |
| 579 | The role of ranibizumab in the management of diabetic retinopathy. 2015 , 10, 329-340 | | 1 |
| 578 | Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?. 2015 , 29, 540-3 | | 13 |
| 577 | Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. <i>Ophthalmology</i> , 2015 , 122, 1811-9 | 7.3 | 30 |
| 576 | Managing Diabetic Eye Disease in Clinical Practice. 2015 , | | 1 |
| 575 | Management of diabetic macular edema. 2015 , 81-103 | | 1 |
| 574 | Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. <i>American Journal of Ophthalmology</i> , 2015 , 159, 915-24.e2 | 4.9 | 125 |
| 573 | Treatment of diabetic maculopathy. 2015 , 76, 35-40 | | 1 |
| 572 | There is level 1 evidence for intensive glycemic control for reducing the progression of diabetic retinopathy in persons with type 2 diabetes. 2015 , 49, 1-3 | | 7 |
| 571 | Molecular mechanisms of diabetic retinopathy: potential therapeutic targets. 2015 , 22, 135-44 | | 50 |
| 570 | Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. 2015 , 372, 1193-203 | | 937 |
| 569 | The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema. <i>Ophthalmology</i> , 2015 , 122, 1416-25 | 7.3 | 24 |
| 568 | Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. <i>Ophthalmology</i> , 2015 , 122, 1375-94 | 7.3 | 278 |
| 567 | Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. 2015 , 6, 234-45 | | 21 |

| | | | |
|-----|--|-----|----|
| 566 | Sustained-release steroids for the treatment of diabetic macular edema. 2015 , 15, 99 | | 11 |
| 565 | Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study. 2015 , 31, 1967-75 | | 13 |
| 564 | Angiotensin-like 4 as an Emerging Therapeutic Target for Diabetic Eye Disease. 2015 , 133, 1375-6 | | 11 |
| 563 | Efficacy and vitreous levels of topical NSAIDs. 2015 , 12, 1767-82 | | 17 |
| 562 | Diabetic macular oedema quantified with spectral-domain optical coherence tomography--evaluation of boundary line artefacts and the effect on retinal thickness. 2015 , 93, 74-82 | | 9 |
| 561 | Planned foveal detachment technique for the resolution of diffuse diabetic macular edema. 2015 , 59, 279-87 | | 12 |
| 560 | Novel Therapies in Development for Diabetic Macular Edema. 2015 , 15, 75 | | 18 |
| 559 | Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy. 2015 , 90, 475-80 | | 10 |
| 558 | Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. <i>Eye</i> , 2015 , 29, 1173-80 | 4.4 | 29 |
| 557 | Reevaluating the definition of intraretinal microvascular abnormalities and neovascularization elsewhere in diabetic retinopathy using optical coherence tomography and fluorescein angiography. <i>American Journal of Ophthalmology</i> , 2015 , 159, 101-10.e1 | 4.9 | 51 |
| 556 | Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. 2015 , 21, 43-51 | | 80 |
| 555 | New treatments for diabetic retinopathy. 2015 , 17, 219-30 | | 37 |
| 554 | Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection. 2016 , 30, 25-31 | | 11 |
| 553 | Increased Levels of Dickkopf 3 in the Aqueous Humor of Patients With Diabetic Macular Edema. 2016 , 57, 2296-304 | | 6 |
| 552 | Current Challenges in Diabetic Retinopathy: Are We Really Doing Better?. 2016 , 31, 254-7 | | 5 |
| 551 | Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice. 2016 , 2016, 2143082 | | 19 |
| 550 | Adjunct Intravitreal Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents. 2016 , 2016, 5282470 | | 3 |
| 549 | Lecithin-Bound Iodine Prevents Disruption of Tight Junctions of Retinal Pigment Epithelial Cells under Hypoxic Stress. 2016 , 2016, 9292346 | | 3 |

| | | | |
|-----|---|-----|----|
| 548 | Use of Mechanical Turk as a MapReduce Framework for Macular OCT Segmentation. 2016 , 2016, 6571547 | | 2 |
| 547 | DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016 , 47, 308-12 | 1.4 | 8 |
| 546 | The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis. 2016 , 11, e0159553 | | 24 |
| 545 | Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. <i>Clinical Ophthalmology</i> , 2016 , 10, 939-46 | 2.5 | 50 |
| 544 | Retinal Hemodynamics Seen on Optical Coherence Tomography Angiography Before and After Treatment of Retinal Vein Occlusion. 2016 , 57, 5681-5687 | | 39 |
| 543 | ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics. <i>Retina</i> , 2016 , 36, 1349-56 | 3.6 | 26 |
| 542 | PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA. <i>Retina</i> , 2016 , 36, 1986-96 | 3.6 | 25 |
| 541 | Symmetry in early response to intravitreal ranibizumab in bilateral diabetic macular oedema. 2016 , 94, e356-60 | | 4 |
| 540 | Characterizing relationship between optical microangiography signals and capillary flow using microfluidic channels. 2016 , 7, 2709-28 | | 34 |
| 539 | Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. <i>British Journal of Ophthalmology</i> , 2016 , 100, 1596-1604 | 5.5 | 43 |
| 538 | Diabetic Retinopathy. 2016 , 554-565 | | |
| 537 | Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group. <i>British Journal of Ophthalmology</i> , 2016 , 100, 1605-1610 | 5.5 | 22 |
| 536 | Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting. 2016 , 236, 207-214 | | 15 |
| 535 | Wide-field optical coherence tomography based microangiography for retinal imaging. 2016 , 6, 22017 | | 89 |
| 534 | Intravitreal Steroid Implants in the Management of Retinal Disease and Uveitis. 2016 , 56, 127-49 | | 4 |
| 533 | Updates on the Management of Diabetic Macular Edema with New-Generation Intravitreal Injectable Drugs. 2016 , 1, 111-128 | | |
| 532 | Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications. 2016 , 29, 44-9 | | 4 |
| 531 | Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER. <i>Ophthalmology</i> , 2016 , 123, 1332-44 | 7.3 | 58 |

| | | | |
|-----|--|-----|----|
| 530 | Intravitreal Anti-VEGF Therapy in the Management of Diabetic Macular Edema. 2016 , 4, 49-55 | | |
| 529 | Effect of Intravitreal Anti-VEGF Therapy on the Severity of Diabetic Retinopathy. 2016 , 4, 61-70 | | 1 |
| 528 | Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. 2016 , 59, 1594-608 | | 31 |
| 527 | The Role of Plasma Kallikrein-Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches. 2016 , 31, 19-24 | | 18 |
| 526 | Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema. <i>Ophthalmology and Therapy</i> , 2016 , 5, 95-104 | 5 | 18 |
| 525 | Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials. <i>Ophthalmology</i> , 2016 , 123, 1511-20 | 7-3 | 42 |
| 524 | Intravitreal Steroid Therapy in the Management of Diabetic Macular Edema. 2016 , 4, 56-60 | | |
| 523 | Vascular endothelial growth factor and diabetic macular edema. <i>Survey of Ophthalmology</i> , 2016 , 61, 759-68 | | 46 |
| 522 | Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections. <i>Eye</i> , 2016 , 30, 718-25 | 4-4 | 16 |
| 521 | Endophthalmitis. 2016 , | | 3 |
| 520 | Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials. 2016 , 134, 160-6 | | 15 |
| 519 | Short-Term Outcomes of Switching to Ranibizumab Therapy for Diabetic Macular Edema in Patients with Persistent Fluid After Bevacizumab Therapy. 2016 , 32, 659-664 | | 10 |
| 518 | Patient-reported outcomes and visual acuity after 12months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting. 2016 , 121, 157-165 | | 25 |
| 517 | Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masked Uveitis TRAtment (SAKURA). <i>Ophthalmology</i> , 2016 , 123, 2413-2423 | 7-3 | 56 |
| 516 | Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. <i>Eye</i> , 2016 , 30, 1531-1541 | 4-4 | 9 |
| 515 | Reply. <i>American Journal of Ophthalmology</i> , 2016 , 170, 245-246 | 4-9 | 1 |
| 514 | Real world evidence of use of anti-VEGF therapy in Denmark. 2016 , 32, 1943-1950 | | 19 |
| 513 | Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE. <i>Ophthalmology</i> , 2016 , 123, 1345-50 | 7-3 | 37 |

| | | | |
|-----|---|-----|-----|
| 512 | Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. <i>Ophthalmology</i> , 2016 , 123, 2376-2385 | 7.3 | 213 |
| 511 | Intravitreal anti-VEGF drug use in industrialized nations: why are newly introduced medications causing us to inject more and not less?. 2016 , 32, 1951-1953 | | |
| 510 | Diabetic retinopathy. 2016 , 2, 16012 | | 367 |
| 509 | Detection of aqueous VEGF concentrations before and after intravitreal injection of anti-VEGF antibody using low-volume sampling paper-based ELISA. 2016 , 6, 34631 | | 30 |
| 508 | Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy. 2016 , 16, 122 | | 20 |
| 507 | Recommendations for the appropriate management of diabetic macular edema: Light on DME survey and consensus document by an expert panel. <i>European Journal of Ophthalmology</i> , 2016 , 26, 252-61 ⁹ | | 8 |
| 506 | Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up. 2016 , 8, 11-6 | | 40 |
| 505 | Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016 , 47, S4-S15 | 1.4 | 5 |
| 504 | South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience. <i>Eye</i> , 2016 , 30, 133-8 | 4.4 | 10 |
| 503 | Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. 2016 , 16, 142 | | 11 |
| 502 | Electronic Patient Records to Identify Patients in the United Kingdom with Diabetic Macular Oedema Suitable for ILUVIEN(®) (Fluocinolone Acetonide). <i>Ophthalmology and Therapy</i> , 2016 , 5, 81-94 | 5 | 1 |
| 501 | The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema. <i>Ophthalmology</i> , 2016 , 123, 1581-7 | 7.3 | 50 |
| 500 | RANIBIZUMAB FOR DIABETIC MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTS. <i>Retina</i> , 2016 , 36, 1292-7 | 3.6 | 18 |
| 499 | Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. <i>Ophthalmology</i> , 2016 , 123, 1716-1721 | 7.3 | 33 |
| 498 | Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study. <i>Ophthalmology</i> , 2016 , 123, 1101-11 | 7.3 | 70 |
| 497 | Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. 2016 , 16, 3 | | 23 |
| 496 | Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects. 2016 , 13, 1277-87 | | 21 |
| 495 | Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes. 2016 , 113, 7213-8 | | 40 |

494 Endophthalmitis After Intravitreal Injections. **2016**, 131-137

| | | | |
|-----|--|-----|-----|
| 493 | RETINAL LAYER RESPONSE TO RANIBIZUMAB DURING TREATMENT OF DIABETIC MACULAR EDEMA: Thinner is Not Always Better. <i>Retina</i> , 2016 , 36, 1314-23 | 3.6 | 13 |
| 492 | Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment. 2016 , 41, 107-113 | | 40 |
| 491 | Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2016 , 164, 57-68 | 4.9 | 95 |
| 490 | Evaluation of ocular pulse amplitude and choroidal thickness in diabetic macular edema. <i>Eye</i> , 2016 , 30, 369-74 | 4.4 | 6 |
| 489 | Ten years of anti-vascular endothelial growth factor therapy. 2016 , 15, 385-403 | | 507 |
| 488 | Evaluation of the New "SAVE" Protocol in Diabetic Macular Edema Over the Course of Anti-VEGF Treatment. 2016 , 41, 1082-1086 | | 5 |
| 487 | The Evolution of Teleophthalmology Programs in the United Kingdom: Beyond Diabetic Retinopathy Screening. 2016 , 10, 308-17 | | 48 |
| 486 | Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions. 2016 , 103, 129-39 | | 16 |
| 485 | Subthreshold Diode Micropulse Laser: A Review. 2016 , 31, 30-9 | | 26 |
| 484 | Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept. <i>American Journal of Ophthalmology</i> , 2016 , 165, 88-93 | 4.9 | 69 |
| 483 | Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 365-74 | 5.4 | 52 |
| 482 | Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis. 2016 , 134, 21-9 | | 130 |
| 481 | [Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study)]. 2016 , 113, 143-51 | | 6 |
| 480 | Diabetic Eye Disease. 2016 , 907-919.e5 | | |
| 479 | Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications. 2017 , 30, 534-540 | | 2 |
| 478 | The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2017 , 101, 75-80 | 5.5 | 40 |
| 477 | Re: Brandt et al.: Human factors and ophthalmic drug packaging: time for a global standard (<i>Ophthalmology</i> 2015;122:2368-2370). <i>Ophthalmology</i> , 2017 , 124, e6-e7 | 7.3 | |

| | | | |
|-----|--|-----|-----|
| 476 | Reply. <i>Ophthalmology</i> , 2017 , 124, e5-e6 | | 7.3 |
| 475 | Evidence-Based Treatment of Diabetic Macular Edema. 2017 , 32, 56-66 | | 11 |
| 474 | Cardiovascular involvement in patients with diabetic macular oedema treated with intravitreal ranibizumab in routine clinical practice. 2017 , 92, 302-306 | | |
| 473 | Comparison of efficacy of intravitreal ranibizumab between non-vitreotomized and vitrectomized eyes with diabetic macular edema. <i>International Ophthalmology</i> , 2018 , 38, 293-299 | 2.2 | 13 |
| 472 | Therapeutic Options in Refractory Diabetic Macular Oedema. 2017 , 77, 481-492 | | 11 |
| 471 | Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection. 2017 , 1, 169-174 | | 23 |
| 470 | Trends in Vitreoretinal Procedures for Medicare Beneficiaries, 2000 to 2014. <i>Ophthalmology</i> , 2017 , 124, 667-673 | 7.3 | 62 |
| 469 | Fluocinolone Acetonide Intravitreal Implant 0.19µg (ILUVIEN): A Review in Diabetic Macular Edema. 2017 , 77, 575-583 | | 16 |
| 468 | Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration. 2017 , 126, 1-9 | | 4 |
| 467 | Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. 2017 , 255, 1453-1454 | | |
| 466 | Impact of intravitreal pharmacotherapies including anti-vascular endothelial growth factor and corticosteroid agents on diabetic retinopathy. 2017 , 28, 213-218 | | 27 |
| 465 | Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy?. 2017 , 60, 131-142 | | 17 |
| 464 | Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2017 , 101, 1689-1693 | 5.5 | 25 |
| 463 | COMBINED INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA: Two-Year Randomized Single-Blind Controlled Trial Results. <i>Retina</i> , 2017 , 37, 1277-1286 | 3.6 | 14 |
| 462 | Targeting Vascular Endothelial Growth Factor. 2017 , 99-139 | | |
| 461 | Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges. 2017 , 34, 1270-1282 | | 24 |
| 460 | Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). 2017 , 237, 185-222 | | 265 |
| 459 | Repeatability of swept-source optical coherence tomography retinal and choroidal thickness measurements in neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2017 , 101, 603-608 | 5.5 | 7 |

| | | | |
|-----|---|-----|-----|
| 458 | Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. 2017 , 135, 558-568 | | 99 |
| 457 | Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. 2017 , 6, CD007419 | | 40 |
| 456 | Autologous Bone Marrow-Derived Cell Therapies for Retinal Disease. 2017 , 79-94 | | |
| 455 | LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study. <i>Retina</i> , 2017 , 37, 2341-2346 | 3.6 | 25 |
| 454 | Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. 2017 , 255, 1259-1273 | | 71 |
| 453 | Effect of intravitreal aflibercept on recalcitrant diabetic macular edema. <i>International Journal of Retina and Vitreous</i> , 2017 , 3, 16 | 2.9 | 20 |
| 452 | Cardiovascular involvement in patients with diabetic macular oedema treated with intravitreal ranibizumab in routine clinical practice. 2017 , 92, 302-306 | | |
| 451 | Predictive factors of better outcomes by monotherapy of an anti-vascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice. 2017 , 96, e6459 | | 15 |
| 450 | Diabetic Macular Edema. 2017 , 58, 102-138 | | 44 |
| 449 | A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. <i>Ophthalmology and Therapy</i> , 2017 , 6, 33-47 | 5 | 27 |
| 448 | Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience. <i>European Journal of Ophthalmology</i> , 2017 , 27, 357-362 | 1.9 | 23 |
| 447 | Diabetic Retinopathy. 2017 , | | 0 |
| 446 | The Clinical Importance of Changes in Diabetic Retinopathy Severity Score. <i>Ophthalmology</i> , 2017 , 124, 596-603 | 7.3 | 28 |
| 445 | Advances in understanding and management of retinopathy of prematurity. <i>Survey of Ophthalmology</i> , 2017 , 62, 257-276 | 6.1 | 68 |
| 444 | Dexamethasone Implant in Chronic Diabetic Macular Edema Resistant to Intravitreal Ranibizumab Treatment. 2017 , 57, 161-165 | | 7 |
| 443 | Current and Emerging Treatment for Diabetic Macular Edema. 2017 , 57, 165-177 | | 5 |
| 442 | Novel therapeutic targets in diabetic macular edema: Beyond VEGF. 2017 , 139, 221-227 | | 41 |
| 441 | Meeting Abstracts. <i>Eye</i> , 2017 , 31, S10-S17 | | 4.4 |

| | | | |
|-----|--|-----|-----|
| 440 | Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. 2017 , 33, 5-17 | | 22 |
| 439 | Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. 2017 , 33, 19-31 | | 11 |
| 438 | Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. 2017 , 33, 33-43 | | 10 |
| 437 | Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting. 2017 , 255, 2165-2171 | | 10 |
| 436 | Animal models of ocular angiogenesis: from development to pathologies. 2017 , 31, 4665-4681 | | 75 |
| 435 | Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol. 2017 , 96, e6406 | | 12 |
| 434 | Diabetic retinopathy, an overview. 2017 , 139, 1-6 | | 23 |
| 433 | Intravitreal aflibercept for proliferative diabetic retinopathy. 2017 , 390, 2141 | | 2 |
| 432 | Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Real-Life Data from a Prospective Study and Predictive Factors for Visual Outcome. 2017 , 8, 1393-1404 | | 24 |
| 431 | Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data. <i>Eye</i> , 2017 , 31, 1594-1599 | 4.4 | 15 |
| 430 | Dexamethasone Implants in Diabetic Macular Edema Patients with High Visual Acuity. 2017 , 58, 125-130 | | 7 |
| 429 | Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2017 , 48, 291-301 | 1.4 | 19 |
| 428 | Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. <i>Ophthalmology</i> , 2017 , 124, 74-81 | 7.3 | 50 |
| 427 | Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation. 2017 , 61, 51-60 | | 25 |
| 426 | Diabetic macular oedema. 2017 , 5, 143-155 | | 127 |
| 425 | Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema. 2017 , 95, 446-459 | | 35 |
| 424 | Efficacy of Topical Oxidoxacin 0.3 % Administration on Conjunctival Bacterial Flora in Diabetic Patients Undergoing Intravitreal Injections. 2017 , 32, 738-742 | | |
| 423 | Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution. 2017 , 112, 218-233 | | 13 |

| | | | |
|-----|---|-----|-----|
| 422 | Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. <i>American Journal of Ophthalmology</i> , 2017 , 173, 56-63 | 4.9 | 23 |
| 421 | Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes. 2017 , 95, 28-32 | | 21 |
| 420 | An overview of the clinical outcomes of the fluocinolone acetonide 190 µg intravitreal implant clinical evidence study in the United Kingdom (ICE-UK). 2017 , 33, 3-4 | | 1 |
| 419 | Relationship between visual outcomes and retinal fluid resorption in patients with diabetic macular edema treated with ranibizumab. 2017 , 40, 839-843 | | |
| 418 | Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept. 2017 , 6, 250-255 | | 19 |
| 417 | Anti-VEGF Therapy for Diabetic Eye Diseases. 2017 , 6, 535-545 | | 33 |
| 416 | Retinal Reflectivity Measurement for Cone Impairment Estimation and Visual Assessment After Diabetic Macular Edema Resolution (RECOVER-DME). 2017 , 58, 6241-6247 | | 11 |
| 415 | Functional and Anatomical Outcomes in Patients With Serous Retinal Detachment in Diabetic Macular Edema Treated With Ranibizumab. 2017 , 58, 797-800 | | 26 |
| 414 | Peptide and Protein-Based Therapeutic Agents*. 2017 , 145-167 | | 6 |
| 413 | Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). <i>Clinical Ophthalmology</i> , 2017 , 11, 393-401 | 2.5 | 71 |
| 412 | Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). 2017 , 2017, 8234186 | | 31 |
| 411 | Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review. 2017 , 2017, 2407037 | | 11 |
| 410 | Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema. 2017 , 2017, 4834201 | | 16 |
| 409 | Author Response: Functional and Anatomic Outcomes in Patients With Serous Retinal Detachment in Diabetic Macular Edema Treated With Ranibizumab. 2017 , 58, 1857 | | |
| 408 | Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. 2017 , 2, | | 374 |
| 407 | Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. 2017 , 17, 158 | | 28 |
| 406 | Ranibizumab for persistent diabetic macular edema after bevacizumab treatment. <i>European Journal of Ophthalmology</i> , 2017 , 27, 210-214 | 1.9 | 12 |
| 405 | Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia. 2017 , 8, 317-329 | | 24 |

| | | | |
|-----|--|-----|----|
| 404 | Efficacy and Safety of Intravitreal Dexamethasone Implants for Treatment of Refractory Diabetic Macular Edema. 2017 , 31, 115-122 | | 19 |
| 403 | Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium. 2018 , 171, 1-11 | | 10 |
| 402 | Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study. 2018 , 136, 315-321 | | 18 |
| 401 | Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema. 2018 , 256, 885-892 | | 22 |
| 400 | Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the 'DR-Pro-DEX Study'. 2018 , 55, 541-547 | | 51 |
| 399 | Clinical Decision-Making when Treating Diabetic Macular Edema Patients with Dexamethasone Intravitreal Implants. 2018 , 240, 61-72 | | 12 |
| 398 | Short-Term Results of Intravitreal Triamcinolone Acetonide Combined with Cataract Surgery for Diabetic Macular Edema in Japan: In the Era of Anti-Vascular Endothelial Growth Factor Therapy. 2018 , 240, 73-80 | | 7 |
| 397 | Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features. 2018 , 239, 205-214 | | 17 |
| 396 | Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. <i>Ophthalmology</i> , 2018 , 125, 683-690 | 7.3 | 31 |
| 395 | Hypertension with diabetes mellitus complications. 2018 , 41, 147-156 | | 43 |
| 394 | Vitrectomy in the management of diabetic macular edema in treatment-naïve patients. 2018 , 53, 402-407 | | 12 |
| 393 | Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study. <i>American Journal of Ophthalmology</i> , 2018 , 187, 138-147 | 4.9 | 10 |
| 392 | The Pattern of Recurrence in Diabetic Macular Edema Treated by Dexamethasone Implant: The PREDIAMEX Study. <i>Ophthalmology Retina</i> , 2018 , 2, 567-573 | 3.8 | 12 |
| 391 | Effect of glycosylated hemoglobin on response to ranibizumab therapy in diabetic macular edema: real-world outcomes in 312 patients. 2018 , 53, 415-419 | | 3 |
| 390 | Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines. 2018 , 96, 267-278 | | 14 |
| 389 | Diabetic macular edema, innovative technologies and economic impact: New opportunities for the Lombardy Region healthcare system?. 2018 , 96, e468-e474 | | 2 |
| 388 | Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections. <i>British Journal of Ophthalmology</i> , 2018 , 102, 1254-1258 | 5.5 | 8 |
| 387 | Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema. 2018 , 239, 94-102 | | 14 |

| | | | |
|-----|---|-----|----|
| 386 | Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. 2018 , 29, 199-205 | | 27 |
| 385 | Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. 2018 , 96, e1-e9 | | 45 |
| 384 | Evaluation of vitreoretinal interface changes in patients receiving intravitreal anti-VEGF therapy. <i>International Ophthalmology</i> , 2018 , 38, 549-556 | 2.2 | 3 |
| 383 | Diabetic macular oedema: evidence-based treatment recommendations for Asian countries. 2018 , 46, 75-86 | | 11 |
| 382 | Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID. <i>Ophthalmology</i> , 2018 , 125, 51-56 | 7.3 | 27 |
| 381 | VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema. <i>International Ophthalmology</i> , 2018 , 38, 2381-2388 | 2.2 | 6 |
| 380 | The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema. 2018 , 96, e377-e385 | | 10 |
| 379 | Estimating Public and Patient Savings From Basic Research-A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy. <i>American Journal of Ophthalmology</i> , 2018 , 185, 115-122 | 4.9 | 26 |
| 378 | Recurrent Diabetic Macular Edema: What to Do. 2017 , 8, 465-474 | | 4 |
| 377 | Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema. <i>Ophthalmology Retina</i> , 2018 , 2, 86-90 | 3.8 | 7 |
| 376 | CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA. <i>Retina</i> , 2018 , 38, 343-351 | 3.6 | 11 |
| 375 | Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. <i>British Journal of Ophthalmology</i> , 2018 , 102, 631-636 | 5.5 | 21 |
| 374 | Patients' Experiences before starting anti-VEGF treatment for sight-threatening diabetic macular oedema: A qualitative interview study. 2018 , 38, 11-17 | | 2 |
| 373 | Therapie des diabetischen Makulaödems. 2018 , 14, 577-589 | | 2 |
| 372 | Aflibercept for diabetic macular oedema: a Meta-analysis of randomized controlled trials. 2018 , 11, 1002-1008 | 1 | |
| 371 | CASES IN REFINING MANAGEMENT OF DIABETIC MACULAR EDEMA. <i>Retina</i> , 2018 , 38 Suppl 1, 1-12 | 3.6 | |
| 370 | Rezidivierendes diabetisches Makulaödem: Was tun?. 2018 , 161-166 | | |
| 369 | Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. 2018 , 10, CD007419 | | 52 |

| | | | |
|-----|--|-----|----|
| 368 | The efficacy and safety of aflibercept and conbercept in diabetic macular edema. 2018 , 12, 3471-3483 | | 21 |
| 367 | Switching to ranibizumab in diabetic macular oedema refractory to bevacizumab treatment. 2018 , 93, 523-529 | | 1 |
| 366 | Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries. <i>Clinical Ophthalmology</i> , 2018 , 12, 2383-2391 | 2.5 | 8 |
| 365 | Molecular Mechanisms Mediating Diabetic Retinal Neurodegeneration: Potential Research Avenues and Therapeutic Targets. 2018 , 66, 445-461 | | 13 |
| 364 | [Peripheral Ischemia in Diabetic Retinopathy and Retinal Vein Occlusion: New Insights with Ultra-Wide-Angle Fundus Imaging and Wide-Angle Fluorescein Angiography]. 2018 , 235, 974-979 | | 2 |
| 363 | Optical coherence tomography findings predictive of response to treatment in diabetic macular edema. 2018 , 46, 4455-4464 | | 7 |
| 362 | Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany. 2018 , 9, 2271-2289 | | 20 |
| 361 | CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report. <i>Retina</i> , 2018 , 38, 1896-1904 | 3.6 | 29 |
| 360 | Evaluation of markers of outcome in real-world treatment of diabetic macular edema. 2018 , 5, 27 | | 15 |
| 359 | Outcomes of Surgically Managed Proliferative Diabetic Retinopathy. 2018 , 2, 338-342 | | |
| 358 | Pathophysiology of diabetic macular edema a background for current treatment modalities. 2018 , 13, 273-281 | | 1 |
| 357 | Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF. 2018 , 32, 643-649 | | 9 |
| 356 | Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Eye Disease. 2018 , 53-78 | | 1 |
| 355 | Evaluation of Vitrectomy with Planned Foveal Detachment as Surgical Treatment for Refractory Diabetic Macular Edema with or without Vitreomacular Interface Abnormality. 2018 , 2018, 9246384 | | 5 |
| 354 | Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factor: Considerations Related to Nonimprovers. <i>Ophthalmology Retina</i> , 2018 , 2, 1133-1142 | 3.8 | 2 |
| 353 | Laser and Light in Ophthalmology. 2018 , 130-139 | | |
| 352 | A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. 2018 , 18, 121 | | 50 |
| 351 | Switching to ranibizumab in diabetic macular oedema refractory to bevacizumab treatment. 2018 , 93, 523-529 | | 1 |

| | | | |
|-----|--|-----|----|
| 350 | Comparison of different settings for yellow subthreshold laser treatment in diabetic macular edema. 2018 , 18, 168 | | 21 |
| 349 | Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE. <i>Ophthalmology</i> , 2018 , 125, 1568-1574 | 7.3 | 24 |
| 348 | A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). 2018 , 96, e942-e949 | | 13 |
| 347 | Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting. <i>American Journal of Ophthalmology</i> , 2018 , 195, 209-222 | 4.9 | 38 |
| 346 | 10 Diabetic Retinopathy. 2018 , | | |
| 345 | Treatment Strategy in Proliferative Diabetic Retinopathy: Anti-VEGF, Laser, or Both?. 2018 , 2, 302-304 | | 1 |
| 344 | Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy. <i>Ophthalmology Retina</i> , 2018 , 2, 997-1009 | 3.8 | 39 |
| 343 | The Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for the treatment of chronic diabetic macular oedema in vitrectomised eyes: a retrospective study. 2018 , 3, e000130 | | 12 |
| 342 | Diabetic Eye Diseases. 2018 , 71-89 | | |
| 341 | Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review. <i>Eye</i> , 2018 , 32, 1423-1431 | 4.4 | 14 |
| 340 | Novel Treatments for Diabetic Retinopathy. 2018 , 123-132 | | |
| 339 | Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach. <i>European Journal of Ophthalmology</i> , 2019 , 29, 82-91 | 1.9 | 13 |
| 338 | Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study). <i>European Journal of Ophthalmology</i> , 2019 , 29, 229-233 | 1.9 | 4 |
| 337 | Effects of kallidinogenase in patients undergoing vitrectomy for diabetic macular edema. <i>International Ophthalmology</i> , 2019 , 39, 1307-1313 | 2.2 | 2 |
| 336 | Real-life experience of ranibizumab for diabetic macular edema in Taiwan. <i>International Ophthalmology</i> , 2019 , 39, 1511-1522 | 2.2 | 11 |
| 335 | Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema. <i>International Ophthalmology</i> , 2019 , 39, 1575-1580 | 2.2 | 6 |
| 334 | Safety of 5914 intravitreal ziv-aflibercept injections. <i>British Journal of Ophthalmology</i> , 2019 , 103, 805-810 | 9.5 | 20 |
| 333 | Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long-term treatment with bevacizumab. 2019 , 47, 287-289 | | 2 |

| | | | |
|-----|--|-----|-----|
| 332 | Advances in the treatment of diabetic retinopathy. 2019 , 33, 107417 | | 27 |
| 331 | Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients. <i>Clinical Ophthalmology</i> , 2019 , 13, 1087-1096 | 2.5 | 5 |
| 330 | Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management: A Potential Cost-Effective Treatment Strategy to Be Explored. <i>Ophthalmology Retina</i> , 2019 , 3, 1009-1011 | 3.8 | 0 |
| 329 | Multiple Effects of Intravitreal Aflibercept on Microvascular Regression in Eyes with Diabetic Macular Edema. <i>Ophthalmology Retina</i> , 2019 , 3, 1067-1075 | 3.8 | 7 |
| 328 | Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index. <i>Ophthalmology Retina</i> , 2019 , 3, 1056-1066 | 3.8 | 17 |
| 327 | Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. 2019 , 9, 10952 | | 23 |
| 326 | Pro Re Nata Dexamethasone Implant for Treatment-Naive Phakic Eyes with Diabetic Macular Edema: A Prospective Study. <i>Ophthalmology Retina</i> , 2019 , 3, 929-937 | 3.8 | 6 |
| 325 | Usefulness of Liquid Biopsy Biomarkers from Aqueous Humor in Predicting Anti-VEGF Response in Diabetic Macular Edema: Results of a Pilot Study. 2019 , 8, | | 13 |
| 324 | Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice. 2019 , 14, e0223793 | | 4 |
| 323 | Subclavian vein stent: Two decades of unassisted patency. 2019 , 23, 504-505 | | |
| 322 | Natural history of diabetic macular edema and factors predicting outcomes in sham-treated patients (MEAD study). 2019 , 257, 2639-2653 | | 4 |
| 321 | Expression of vascular infarction-related molecules after anti-vascular endothelium growth factor treatment for diabetic macular edema. 2019 , 9, 12373 | | 3 |
| 320 | ETDRS Grading of Diabetic Retinopathy: Still the Gold Standard?. 2019 , 62, 190-195 | | 31 |
| 319 | Primary outcomes of the VIDJ study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema. <i>International Journal of Retina and Vitreous</i> , 2019 , 5, 28 | 2.9 | 7 |
| 318 | Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy. 2019 , 19, 106 | | 10 |
| 317 | Induced Expression of VEGFC, ANGPT, and EFNB2 and Their Receptors Characterizes Neovascularization in Proliferative Diabetic Retinopathy. 2019 , 60, 4084-4096 | | 11 |
| 316 | Deep learning algorithm predicts diabetic retinopathy progression in individual patients. 2019 , 2, 92 | | 100 |
| 315 | Endomucin restores depleted endothelial glycocalyx in the retinas of streptozotocin-induced diabetic rats. 2019 , 33, 13346-13357 | | 11 |

| | | | |
|-----|---|-----|-----|
| 314 | Healthcare resource use and costs of diabetic macular oedema for patients with anti-vascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study. 2019 , 9, e030930 | | 8 |
| 313 | Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity. 2019 , 11, 25-35 | | 6 |
| 312 | One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema. 2019 , 241, 220-225 | | 12 |
| 311 | AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes. <i>Retina</i> , 2019 , 39, 61-68 | 3.6 | 15 |
| 310 | Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept. <i>Clinical Ophthalmology</i> , 2019 , 13, 695-700 | 2.5 | 4 |
| 309 | Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment. 2019 , 19, 123 | | 10 |
| 308 | Prefilled syringes for intravitreal drug delivery. <i>Clinical Ophthalmology</i> , 2019 , 13, 701-706 | 2.5 | 15 |
| 307 | ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY CAN IMPROVE DIABETIC RETINOPATHY SCORE WITHOUT CHANGE IN RETINAL PERFUSION. <i>Retina</i> , 2019 , 39, 426-434 | 3.6 | 36 |
| 306 | The Role of Steroids in the Management of Diabetic Macular Edema. 2019 , 62, 231-236 | | 55 |
| 305 | Evidence-Based Guidelines for Management of Diabetic Macular Edema. 2019 , 3, 145-152 | | 4 |
| 304 | Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. 2019 , 321, 1880-1894 | | 94 |
| 303 | Simultaneous Inhibition of Angiotensin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. <i>Ophthalmology</i> , 2019 , 126, 1155-1170 ³ | | 95 |
| 302 | VEGF in Signaling and Disease: Beyond Discovery and Development. 2019 , 176, 1248-1264 | | 617 |
| 301 | Diabetic Retinopathy and Its Management. 2019 , 39-51 | | |
| 300 | Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2019 , 206, 74-81 | 4.9 | 11 |
| 299 | Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach. 2019 , 80, 34-39 | | 1 |
| 298 | Blood Pressure Is Associated with Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Patients with Diabetes. <i>Ophthalmology Retina</i> , 2019 , 3, 410-416 | 3.8 | 8 |
| 297 | Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. <i>American Journal of Ophthalmology</i> , 2019 , 202, 91-99 | 4.9 | 27 |

| | | | |
|-----|---|-----|----|
| 296 | Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies. <i>Ophthalmology</i> , 2019 , 126, 712-720 | 7.3 | 14 |
| 295 | Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study. <i>British Journal of Ophthalmology</i> , 2020 , 104, 1209-1215 | 5.5 | 10 |
| 294 | Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema. 2019 , 4, e000335 | | 1 |
| 293 | Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema. <i>Clinical Ophthalmology</i> , 2019 , 13, 2583-2590 | 2.5 | 1 |
| 292 | Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results. <i>Ophthalmology Retina</i> , 2019 , 3, 917-919 | 3.8 | 3 |
| 291 | Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema. 2019 , 2019, 6274209 | | 0 |
| 290 | Emerging Concepts in the Treatment of Diabetic Retinopathy. 2019 , 19, 137 | | 13 |
| 289 | Advancing Insights Into Diabetic Eye Disease: 5th Annual American Society of Retina Specialists Presidents/Young Investigator Award Lecture. 2019 , 3, 384-389 | | |
| 288 | Diabetic Retinopathy-An Underdiagnosed and Undertreated Inflammatory, Neuro-Vascular Complication of Diabetes. 2019 , 10, 843 | | 26 |
| 287 | Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture. 2018 , 7, 36-39 | | 6 |
| 286 | Diabetic Macular Edema: Current Understanding, Pharmacologic Treatment Options, and Developing Therapies. 2018 , 7, 28-35 | | 31 |
| 285 | CHALLENGING THE STATUS QUO IN DME. <i>Retina</i> , 2019 , 39 Suppl 3, S1-S12 | 3.6 | |
| 284 | Anti-Vascular Endothelial Growth Factor Therapy and Cardiovascular Disease Risk. 2019 , 100-105 | | |
| 283 | Impact of ranibizumab on visual impairment in patients with bilateral diabetic macular edema. 2019 , 56, 67-71 | | 2 |
| 282 | LONG-TERM VISUAL OUTCOMES AND CLINICAL FEATURES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION-RELATED ENDOPHTHALMITIS. <i>Retina</i> , 2019 , 39, 2070-2076 | 3.6 | 12 |
| 281 | Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. 2019 , 35, 1165-1176 | | 4 |
| 280 | Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. 2019 , 19, 15 | | 42 |
| 279 | Association of Intravitreal Injections With Blood Pressure Increase: The Following Excitement and Anxiety Response Under Intravitreal Injection Study. 2019 , 137, 87-90 | | 11 |

| | | | |
|-----|---|-----|----|
| 278 | The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. 2019 , 69, 116-136 | | 38 |
| 277 | Vitreous and intraretinal macular changes in diabetic macular edema with and without tractional components. 2019 , 257, 1-8 | | 12 |
| 276 | Diabetic Macular Edema. 2019 , 97-183 | | |
| 275 | Management of diabetic macular edema patients in clinical practice in Spain. <i>European Journal of Ophthalmology</i> , 2019 , 29, 664-672 | 1.9 | 3 |
| 274 | Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. <i>Ophthalmology</i> , 2019 , 126, 87-95 | 7.3 | 43 |
| 273 | Planned Foveal Detachment Technique for the Resolution of Diabetic Macular Edema Resistant to Anti-Vascular Endothelial Growth Factor Therapy. <i>Retina</i> , 2019 , 39 Suppl 1, S162-S168 | 3.6 | 4 |
| 272 | [Cost Comparison of Licensed Intravitreal Therapies for Insufficiently Anti-VEGF Responding Fovea Involving Diabetic Macular Edema in Germany]. 2019 , 236, 180-191 | | 7 |
| 271 | THREE-YEAR OUTCOMES IN A RANDOMIZED SINGLE-BLIND CONTROLLED TRIAL OF INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA. <i>Retina</i> , 2019 , 39, 1083-1090 | 3.6 | 12 |
| 270 | Treatment outcomes and predicting factors for diabetic macular edema treated with ranibizumab - One-year real-life results in Taiwan. 2019 , 118, 194-202 | | 12 |
| 269 | Predictive factors for patients receiving intravitreal anti-vascular endothelial growth factor for the treatment of diabetic macular edema. <i>European Journal of Ophthalmology</i> , 2020 , 30, 72-80 | 1.9 | 2 |
| 268 | Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients?. <i>European Journal of Ophthalmology</i> , 2020 , 30, 1091-1098 | 1.9 | 12 |
| 267 | Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN (0.19 mg fluocinolone acetonide implant). <i>European Journal of Ophthalmology</i> , 2020 , 30, 382-391 | 1.9 | 32 |
| 266 | Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes. <i>European Journal of Ophthalmology</i> , 2020 , 30, 557-562 | 1.9 | 11 |
| 265 | Evolution of intravitreal therapy for retinal and macular disorders. 2020 , 48, 300060518771411 | | 1 |
| 264 | Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study. <i>Ophthalmology Retina</i> , 2020 , 4, 57-66 | 3.8 | 6 |
| 263 | Evolving role of anti-VEGF for diabetic macular oedema: from clinical trials to real life. <i>Eye</i> , 2020 , 34, 415-417 | 4.4 | 5 |
| 262 | Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. 2020 , 98, e217-e223 | | 47 |
| 261 | Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study. <i>International Ophthalmology</i> , 2020 , 40, 67-72 | 2.2 | 4 |

| | | | |
|-----|--|-----|-----|
| 260 | Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. <i>Eye</i> , 2020 , 34, 480-490 | 4.4 | 11 |
| 259 | Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data. 2020 , 23, 287-296 | | 6 |
| 258 | Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections. 2020 , 35, 2-6 | | 8 |
| 257 | Diabetic Retinopathy Preferred Practice Pattern . <i>Ophthalmology</i> , 2020 , 127, P66-P145 | 7.3 | 113 |
| 256 | Retinal Vein Occlusions Preferred Practice Pattern . <i>Ophthalmology</i> , 2020 , 127, P288-P320 | 7.3 | 15 |
| 255 | Predicting optical coherence tomography-derived diabetic macular edema grades from fundus photographs using deep learning. 2020 , 11, 130 | | 42 |
| 254 | Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial. 2020 , 258, 479-490 | | 2 |
| 253 | The role of steroids in treating diabetic macular oedema in the era of anti-VEGF. <i>Eye</i> , 2020 , 34, 1003-1005 | 4.4 | 4 |
| 252 | Intravitreal anti-VEGF agents and cardiovascular risk. 2020 , 15, 199-210 | | 19 |
| 251 | Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: association with intravitreal injection treatment profiles in real-world setting. 2020 , 98, e421-e427 | | 1 |
| 250 | Real-world Outcomes among Eyes with Center-Involving Diabetic Macular Edema and Good Visual Acuity. 2020 , 45, 879-887 | | 1 |
| 249 | Impact of Intravitreal Ranibizumab Therapy on Vision Outcomes in Diabetic Macular Edema Patients: A Meta-Analysis. 2020 , 243, 243-254 | | 3 |
| 248 | Diabetic retinopathy, diabetic macular edema, and cardiovascular risk: the importance of a long-term perspective and a multidisciplinary approach to optimal intravitreal therapy. 2020 , 57, 513-526 | | 11 |
| 247 | Anti-VEGF agents in the management of diabetic macular edema. 2020 , 15, 285-296 | | 3 |
| 246 | Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study). <i>Clinical Ophthalmology</i> , 2020 , 14, 4173-4185 | 2.5 | 5 |
| 245 | Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes. 2020 , 20, 443 | | 3 |
| 244 | Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN clinical evidence study in Portugal. 2020 , 12, 2515841420917768 | | 1 |
| 243 | Prospective, Single-Center, Six-Month Study of Intravitreal Ranibizumab for Macular Edema with Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-Perfused Retinal Area. <i>Clinical Ophthalmology</i> , 2020 , 14, 1609-1618 | 2.5 | 4 |

| | | | |
|-----|--|-----|----|
| 242 | Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial. 2020 , 138, 945-953 | | 21 |
| 241 | New developments in angiography for the diagnosis and management of diabetic retinopathy. 2020 , 167, 108361 | | 5 |
| 240 | Emerging corticosteroid delivery platforms for treatment of diabetic macular edema. 2020 , 25, 383-394 | | 1 |
| 239 | Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases. 2020 , | | 0 |
| 238 | Recurrent Blood Pressure Rise after Treatment with Anti-vascular Endothelial Growth Factor Agents. 2020 , 237, 454-457 | | 1 |
| 237 | Targeted IgMs agonize ocular targets with extended vitreal exposure. 2020 , 12, 1818436 | | 2 |
| 236 | Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema. 2020 , 2020, 7239570 | | 3 |
| 235 | Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN) and Follow-Up Considerations/Recommendations. <i>Clinical Ophthalmology</i> , 2020 , 14, 2091-2107 | 2.5 | 2 |
| 234 | Histamine causes an imbalance between pro-angiogenic and anti-angiogenic factors in the retinal pigment epithelium of diabetic retina via H4 receptor/p38 MAPK axis. 2020 , 8, | | 4 |
| 233 | CRISPR Technology for Ocular Angiogenesis. 2020 , 2, 594984 | | 2 |
| 232 | Impact of Intravitreal Ranibizumab Therapy on Vision Outcomes in Diabetic Macular Edema Patients: A Meta-Analysis. 2020 , 6, 2-10 | | |
| 231 | HbA1c as a predictor for response of bevacizumab in diabetic macular oedema. 2020 , 5, e000449 | | 6 |
| 230 | Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes. <i>European Journal of Ophthalmology</i> , 2021 , 31, 1201-1207 | 1.9 | 2 |
| 229 | Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial. <i>Ophthalmology Retina</i> , 2020 , 4, 777-788 | 3.8 | 5 |
| 228 | Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: Early versus late switch. <i>European Journal of Ophthalmology</i> , 2021 , 31, 1135-1145 | 1.9 | 7 |
| 227 | Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study. 2020 , 15, e0233595 | | 16 |
| 226 | Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China. 2020 , 20, 229 | | 3 |
| 225 | Retinal Vascular Disease. 2020 , | | 1 |

| | | | |
|-----|---|-----|----|
| 224 | Survey of Intravitreal Injection Practice Patterns Among Retina Specialists. 2020 , 4, 306-311 | | 0 |
| 223 | A New Approach for Diabetic Macular Edema Treatment: review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes. 2020 , 8, 1-10 | | 7 |
| 222 | The fellow eye effect of unilateral intravitreal conbercept injections in eyes with diabetic macular edema. 2020 , 57, 1001-1007 | | 3 |
| 221 | Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials. <i>Clinical Ophthalmology</i> , 2020 , 14, 1629-1639 | 2.5 | 0 |
| 220 | The Short-term Effect of a Single Lapse in Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema Within Routine Clinical Practice. <i>American Journal of Ophthalmology</i> , 2020 , 219, 215-221 | 4.9 | 9 |
| 219 | Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema. <i>International Journal of Retina and Vitreous</i> , 2020 , 6, 17 | 2.9 | 3 |
| 218 | The Renin-Angiotensin-Aldosterone System (RAAS) Is One of the Effectors by Which Vascular Endothelial Growth Factor (VEGF)/Anti-VEGF Controls the Endothelial Cell Barrier. 2020 , 190, 1971-1981 | | 8 |
| 217 | A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolicizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE). 2020 , 237, 450-453 | | 8 |
| 216 | PPAR α activation directly upregulates thrombomodulin in the diabetic retina. 2020 , 10, 10837 | | 11 |
| 215 | Diabetic Retinopathy Screening Using a Gold Nanoparticle-Based Paper Strip Assay for the At-Home Detection of the Urinary Biomarker 8-Hydroxy-2'-Deoxyguanosine. <i>American Journal of Ophthalmology</i> , 2020 , 213, 306-319 | 4.9 | 9 |
| 214 | Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict morphological features and timing of recurrence in patients treated with dexamethasone intravitreal implants. 2020 , 57, 867-874 | | 3 |
| 213 | Advances in intravitreal therapy and implants: where are we now?. 2020 , 11, 69-73 | | 4 |
| 212 | Current concepts of pharmacotherapy of diabetic macular edema. 2020 , 21, 467-475 | | 12 |
| 211 | Predictive factors of outcome of selective retina therapy for diabetic macular edema. <i>International Ophthalmology</i> , 2020 , 40, 1221-1232 | 2.2 | 4 |
| 210 | American Society of Retina Specialists Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy without Diabetic Macular Edema. 2020 , 4, 125-135 | | 6 |
| 209 | [Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Situation August 2019]. 2020 , 117, 218-247 | | 4 |
| 208 | Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies. 2020 , 54, 750-756 | | 3 |
| 207 | Real-Life Management of Diabetic Macular Edema with Dexamethasone Intravitreal Implant: A Retrospective Analysis of Long-Term Clinical Outcomes. 2020 , 2020, 4860743 | | 1 |

| | | | |
|-----|--|-----|----|
| 206 | Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema. 2020 , 36, 959-965 | | 1 |
| 205 | Genotypes and Phenotypes: A Search for Influential Genes in Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 13 |
| 204 | Management of diabetic macular edema: experts' consensus in Taiwan. 2020 , 64, 235-242 | | 3 |
| 203 | Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients. <i>Clinical Ophthalmology</i> , 2020 , 14, 921-929 | 2.5 | 4 |
| 202 | Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. <i>British Journal of Ophthalmology</i> , 2021 , 105, 253-257 | 5.5 | 1 |
| 201 | [Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper]. 2021 , 238, 73-84 | | 4 |
| 200 | Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. <i>Ophthalmology</i> , 2021 , 128, 417-424 | 7.3 | 13 |
| 199 | Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema. 2021 , 259, 815-836 | | 5 |
| 198 | Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Dated August 2019. 2021 , 118, 40-67 | | 0 |
| 197 | Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States. 2021 , 5, 108-113 | | |
| 196 | Association Between First- and Third-Month Responses to Intravitreal Ranibizumab for Diabetic Macular Edema. 2021 , 5, 99-107 | | 0 |
| 195 | Retinal Fluid Volatility Associated With Interval Tolerance and Visual Outcomes in Diabetic Macular Edema in the VISTA Phase III Trial. <i>American Journal of Ophthalmology</i> , 2021 , 224, 217-227 | 4.9 | 2 |
| 194 | [The modified treat and extend scheme with injection blocks in intravitreal injection treatment : Retrospective analysis from the routine clinical application]. 2021 , 118, 578-586 | | 0 |
| 193 | SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials. <i>American Journal of Ophthalmology</i> , 2021 , 222, 185-193 | 4.9 | |
| 192 | Non-invasive multimodal imaging of Diabetic Retinopathy: A survey on treatment methods and Nanotheranostics. 2021 , 5, 166-181 | | 2 |
| 191 | Translation and content validity of the Dutch Impact of Vision Impairment questionnaire assessed by Three-Step Test-Interviewing. 2021 , 5, 1 | | 9 |
| 190 | Comparison of the intraocular pressure following an intravitreal triamcinolone acetonide injection for diabetic macula oedema in vitrectomised and non-vitrectomised eyes. 2021 , 6, e000620 | | 0 |
| 189 | Impact of treatment of diabetic macular edema on visual impairment in people with diabetes mellitus in India. <i>Indian Journal of Ophthalmology</i> , 2021 , 69, 671-676 | 1.6 | 2 |

| | | | |
|-----|---|-----|----|
| 188 | One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders. <i>Indian Journal of Ophthalmology</i> , 2021 , 69, 360-367 | 1.6 | 4 |
| 187 | Exosome-mediated delivery of an anti-angiogenic peptide inhibits pathological retinal angiogenesis. 2021 , 11, 5107-5126 | | 12 |
| 186 | Diabetic eye disease: A review of screening and management recommendations. 2021 , 49, 128-145 | | 5 |
| 185 | Title: efficacy of intravitreal dexamethasone implant on hard exudate in diabetic macular edema. 2021 , 21, 41 | | 3 |
| 184 | Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options. <i>Clinical Ophthalmology</i> , 2021 , 15, 375-385 | 2.5 | 3 |
| 183 | Automatic prediction of treatment outcomes in patients with diabetic macular edema using ensemble machine learning. 2021 , 9, 43 | | 9 |
| 182 | Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial. 2021 , 65, 354-362 | | 2 |
| 181 | VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 6 |
| 180 | Intravitreal Therapy for Diabetic Macular Edema: An Update. 2021 , 2021, 6654168 | | 5 |
| 179 | Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema. 2021 , 11, 4488 | | 4 |
| 178 | Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results. <i>European Journal of Ophthalmology</i> , 2021 , 1120672121992982 | 1.9 | 2 |
| 177 | Intravitreal Ranibizumab Versus Aflibercept for Diabetic Macular Edema in Vitrectomized Eyes: 12 Month Results. 2021 , 36, 723-727 | | 1 |
| 176 | Real-world outcomes of two-year Conbercept therapy for diabetic macular edema. 2021 , 14, 416-422 | | 2 |
| 175 | Biomarkers for Progression in Diabetic Retinopathy: Expanding Personalized Medicine through Integration of AI with Electronic Health Records. 2021 , 36, 250-257 | | 3 |
| 174 | The stress response protein REDD1 as a causal factor for oxidative stress in diabetic retinopathy. 2021 , 165, 127-136 | | 2 |
| 173 | Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema. 2021 , 16, 17-31 | | |
| 172 | Intravitreal Aflibercept versus Ranibizumab for Diabetic Macular Edema in a Taiwanese Health Service Setting. 2021 , 36, 132-138 | | 1 |
| 171 | Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy. <i>International Journal of Retina and Vitreous</i> , 2021 , 7, 30 | 2.9 | 2 |

| | | | |
|-----|---|-----|---|
| 170 | Vascular Expression of Permeability-Resistant Occludin Mutant Preserves Visual Function in Diabetes. <i>Diabetes</i> , 2021 , 70, 1549-1560 | 0.9 | 5 |
| 169 | Racial Differences in Anti-VEGF Intravitreal Injections Among Commercially Insured Beneficiaries. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2021 , 52, 208-217 | 1.4 | 0 |
| 168 | AMP-activated protein kinase is a key regulator of acute neurovascular permeability. 2021 , 134, | | 5 |
| 167 | Comparison of Two Spectral-domain Optical Coherence Tomography Scan Modes for Measuring Retinal Vessel Diameter. 2021 , 46, 1025-1030 | | |
| 166 | Indicators of Visual Prognosis in Diabetic Macular Oedema. 2021 , 11, | | 1 |
| 165 | Galectins in the Pathogenesis of Common Retinal Disease. <i>Frontiers in Pharmacology</i> , 2021 , 12, 687495 | 5.6 | 0 |
| 164 | Diabetic macular edema. 2021 , 67, 101138 | | 5 |
| 163 | Ranibizumab for the treatment of diabetic retinopathy. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 991-997 | 5.4 | 2 |
| 162 | The prognostic role of optical coherence tomography in diabetic macular edema patients undergoing early dexamethasone implant shift. <i>European Journal of Ophthalmology</i> , 2021 , 11206721211019569 | 1.9 | 1 |
| 161 | The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up study. 2021 , | | 1 |
| 160 | Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials. 2021 , | | 7 |
| 159 | Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis. 2021 , 173, 439-460 | | 3 |
| 158 | THE EFFECT OF ENDOPHTHALMITIS ON RECURRENCE OF MACULAR EDEMA IN EYES RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR. <i>Retina</i> , 2021 , 41, 1470-1477 | 3.6 | 2 |
| 157 | Outcomes of Eyes With Diabetic Macular Edema That Are Lost to Follow-up After Anti-Vascular Endothelial Growth Factor Therapy. <i>American Journal of Ophthalmology</i> , 2021 , 233, 1-7 | 4.9 | 1 |
| 156 | Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF. 2021 , 2021, 9967831 | | |
| 155 | Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature. 2021 , 13, | | 4 |
| 154 | Perfect use versus typical use: translating outcomes in the treatment of diabetic macular oedema. <i>Eye</i> , 2021 , | 4.4 | 0 |
| 153 | Clinical Research of Selective Retina Therapy (SRT) for Retinal Diseases. 2021 , 42, 89-95 | | |

| | | | |
|-----|--|-----|----|
| 152 | Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study. <i>Eye</i> , 2021 , | 4.4 | 1 |
| 151 | Challenges in Diabetic Macular Edema Management: An Expert Consensus Report. <i>Clinical Ophthalmology</i> , 2021 , 15, 3183-3195 | 2.5 | 3 |
| 150 | Toward a New Staging System for Diabetic Retinopathy Using Wide Field Swept-Source Optical Coherence Tomography Angiography. 2021 , 21, 28 | | 2 |
| 149 | Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy. <i>Eye</i> , 2021 , | 4.4 | 5 |
| 148 | Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. <i>Ophthalmology</i> , 2021 , | 7.3 | 3 |
| 147 | Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study. <i>British Journal of Ophthalmology</i> , 2021 , | 5.5 | 0 |
| 146 | Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial. 2021 , 18, 825-832 | | 0 |
| 145 | Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. 2021 , 139, 946-955 | | 11 |
| 144 | Real-Time Diabetic Retinopathy Severity Score Level versus Ultra-Widefield Leakage Index-Guided Management of Diabetic Retinopathy: Two-Year Outcomes from the Randomized PRIME Trial. 2021 , 11, | | 0 |
| 143 | Visual/anatomical outcome of diabetic macular edema patients lost to follow-up for more than 1 year. 2021 , 11, 18353 | | 1 |
| 142 | The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown. 2021 , 35, 102449 | | 2 |
| 141 | Efficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema: a systematic review and meta-analysis. 2021 , 1 | | 2 |
| 140 | Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema. 2021 , 1, 100040 | | 4 |
| 139 | Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review. 2021 , 13, | | 2 |
| 138 | Early Conversion to Aflibercept for Persistent Diabetic Macular Edema Results in Better Visual Outcomes and Lower Treatment Costs. <i>Clinical Ophthalmology</i> , 2021 , 15, 31-39 | 2.5 | 2 |
| 137 | [Dexamethasone intravitreal implant (Ozurdex) in patients with diabetic macular edema: Real life safety and efficacy]. 2020 , 43, 197-204 | | 1 |
| 136 | Real-world experience with 0.2 µ/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. <i>Eye</i> , 2017 , 31, 1707-1715 | 4.4 | 60 |
| 135 | Recent advances in the management and understanding of diabetic retinopathy. 2017 , 6, 2063 | | 14 |

| | | | |
|-----|---|-----|----|
| 134 | Emerging therapies in the management of macular edema: a review. 2019 , 8, | | 21 |
| 133 | Peripapillary intrachoroidal cavitations. The Beijing eye study. 2013 , 8, e78743 | | 16 |
| 132 | Enface Thickness Mapping and Reflectance Imaging of Retinal Layers in Diabetic Retinopathy. 2015 , 10, e0145628 | | 8 |
| 131 | [Neurodegenerative biomarkers of the response to diabetic macular edema treatment]. 2020 , 136, 201-206 | | 0 |
| 130 | Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment. 2017 , 13, 91-98 | | 1 |
| 129 | Prognostic factors of short-term outcomes of intravitreal ranibizumab in diabetic macular edema. 2017 , 10, 765-771 | | 5 |
| 128 | Bimodal imaging of proliferative diabetic retinopathy vascular features using swept source optical coherence tomography angiography. 2018 , 11, 1528-1533 | | 13 |
| 127 | Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity. 2020 , 13, 1606-1611 | | 2 |
| 126 | Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation. 2016 , 12, 527-33 | | 7 |
| 125 | Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Nontractional Diabetic Macular Edema. 2017 , 11, 5-10 | | 8 |
| 124 | An observational study to assess if automated diabetic retinopathy image assessment software can replace one or more steps of manual imaging grading and to determine their cost-effectiveness. 2016 , 20, 1-72 | | 56 |
| 123 | Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015 , 46, 302-5 | 1.4 | 12 |
| 122 | Primary intravitreal ranibizumab for high-risk retinopathy of prematurity. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015 , 46, 432-8 | 1.4 | 16 |
| 121 | Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015 , 46, 950-4 | 1.4 | 40 |
| 120 | Diabetic Macular Edema Diagnosis and Treatment in the Real World: An Analysis of Medicare Claims Data (2008 to 2010). <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016 , 47, 258-67 | 1.4 | 26 |
| 119 | Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016 , 47, 426-35 | 1.4 | 25 |
| 118 | Comparison of Ranibizumab 0.5 mg Versus 1.0 mg for the Treatment of Patients With Clinically Significant Diabetic Macular Edema: A Randomized, Clinical Trial. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016 , 47, 536-43 | 1.4 | 3 |
| 117 | Evaluation and Referral of Diabetic Eye Disease in the Endocrinology and Primary Care Office Settings. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016 , 47, 930-934 | 1.4 | 1 |

| | | | |
|-----|---|-----|----|
| 116 | Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2017 , 48, 230-236 | 1.4 | 17 |
| 115 | High-Dose Decanted Triamcinolone for Treatment-Resistant Persistent Macular Edema. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2017 , 48, 717-726 | 1.4 | 2 |
| 114 | When and How to Incorporate Steroids for Persistent Diabetic Macular Edema: A Discussion of Real-World Treatment Optimization Strategies. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018 , 49, S5-S15 | 1.4 | 7 |
| 113 | Characterization of the Systemic Findings of Patients Undergoing Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Routine Clinical Practice. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2019 , 50, 16-24 | 1.4 | 2 |
| 112 | Baseline Ocular Characteristics of Patients Undergoing Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2019 , 50, 69-75 | 1.4 | 0 |
| 111 | An International Comparison of Baseline Characteristics of Patients Undergoing Initiation of Anti-VEGF Therapy for DME. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2019 , 50, e300-e310 | 1.4 | 1 |
| 110 | Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. <i>Indian Journal of Ophthalmology</i> , 2016 , 64, 14-25 | 1.6 | 13 |
| 109 | Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?. <i>Indian Journal of Ophthalmology</i> , 2016 , 64, 4-13 | 1.6 | 17 |
| 108 | Updates on the Clinical Trials in Diabetic Macular Edema. 2016 , 23, 3-12 | | 7 |
| 107 | Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases. <i>Indian Journal of Ophthalmology</i> , 2017 , 65, 559-568 | 1.6 | 2 |
| 106 | Revisiting pars plana vitrectomy in the primary treatment of diabetic macular edema in the era of pharmacological treatment. 2019 , 9, 224-232 | | 3 |
| 105 | Corticosteroids for Diabetic Macular Edema. 2019 , 9, 233-242 | | 11 |
| 104 | Corticosteroid Treatment in Diabetic Macular Edema. 2017 , 47, 156-160 | | 13 |
| 103 | Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports. 2015 , 21, 8-10 | | 21 |
| 102 | Prevention and management of diabetic retinopathy. 2014 , 57, 525 | | |
| 101 | Encyclopedia of Ophthalmology. 2014 , 1-3 | | |
| 100 | Diabetes Mellitus and Metabolic Syndrome. 2015 , 55-79 | | |
| 99 | New treatments for diabetic macular edema. 2015 , 5, 45 | | |

- 98 Diabetic macular edema: Efficacy and safety of anti-vascular endothelial growth factor therapy. **2015**, 5, 133
- 97 Curing diabetic retinopathy: Is a strategy emerging?. **2015**, 5, 142
- 96 Long-Term Outcome of Approved Pharmacotherapy for Diabetic Macular Edema: A Review of Randomized Controlled Trials in Fluocinolone Acetonide Implants, Dexamethasone Implants, Aflibercept and Ranibizumab. 015-018
- 95 New Modalities for the Diagnosis and Treatment of Diabetic Retinopathy. **2015**, 89, 271-276 2
- 94 Diabetic Retinopathy. **2016**, 29-42
- 93 Encyclopedia of Ophthalmology. **2016**, 1-10
- 92 Current Treatment Recommendations. **2017**, 163-186
- 91 Encyclopedia of Ophthalmology. **2017**, 1-10
- 90 DİYABETİK MAKÜLA DEMANIN FARMAKOLOJİK YAKLAŞIMLARINDA GÜNCEL GELİMLER: İNTRAVİTRAL ENJEKSİYON UYGULAMALARI VE SİSTEMLERİNİN SALINIM SİSTEMLERİ **2017**, 18, 37-43
- 89 Anti-angiogenesis Therapy in Diabetic Retinopathy. **2017**, 299-323
- 88 Encyclopedia of Ophthalmology. **2018**, 1211-1213
- 87 Encyclopedia of Ophthalmology. **2018**, 614-624
- 86 Diabetisches Makulaödem: Eine Standortbestimmung.
- 85 Combination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.net Protocol U. 1, 2
- 84 AMP-activated protein kinase is a key regulator of acute neurovascular permeability.
- 83 [The role of internal limiting membrane peeling in the treatment of diabetic macular edema]. **2020**, 136, 359-366 0
- 82 Applications of Artificial Intelligence for the Detection, Management, and Treatment of Diabetic Retinopathy. **2020**, 60, 127-145 0
- 81 Quantification of Diabetic Retinopathy Lesions in DME Patients With Intravitreal Conbercept Treatment Using Deep Learning. *Ophthalmic Surgery Lasers and Imaging Retina*, **2020**, 51, 95-100 1.4 0

| | | | |
|----|--|-----|---|
| 80 | Diabetic Retinopathy [Clinical. 2020 , 59-78 | | 0 |
| 79 | Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema. <i>Clinical Ophthalmology</i> , 2020 , 14, 1249-1259 | 2.5 | 0 |
| 78 | Medical Management of Diabetic Retinopathy. 2020 , 19-33 | | |
| 77 | Posterior Segment. 2020 , 299-338 | | |
| 76 | Efficacy of Intravitreal Dexamethasone Implant for Diabetic Macular Edema According to Previous Responses to Bevacizumab. 2020 , 61, 51 | | |
| 75 | Patient Management in Clinical Practice. 2020 , 63-165 | | |
| 74 | Emerging Therapeutic Modalities for Diabetic Retinopathy. 2020 , 161-187 | | 0 |
| 73 | Yaşlı Tip Senil Makula Dejeneresansı olan Hastalarda İntavitreal Enjeksiyonun Oküler Kardiyak Refleks Üzerine Etkisi. <i>Dicle Medical Journal</i> , 202-207 | | 0 |
| 72 | Long-Term Vision Outcomes in Patients With DME and a Limited Early Visual Response to Ranibizumab in RIDE and RISE. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2020 , 51, 210-218 | 1.4 | 1 |
| 71 | Diagnosis and Management of Ophthalmic Complications of Diabetes. 2021 , 252-268 | | |
| 70 | Incidence and Clinical Features of Rhegmatogenous Retinal Detachment After 9,484 Intravitreal Injections by a Single Physician. <i>Journal of Retina</i> , 2020 , 5, 79-84 | 0.2 | |
| 69 | Modern Strategies to Save Sight in Diabetes. <i>Missouri Medicine</i> , 2016 , 113, 372-377 | 0.8 | |
| 68 | Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement. <i>Indian Journal of Ophthalmology</i> , 2021 , 69, 3076-3086 | 1.6 | 0 |
| 67 | Treatment patterns and persistence rates with anti-VEGF treatment for diabetic macular edema in the UK: a real-world study. <i>Diabetic Medicine</i> , 2021 , e14746 | 3.5 | 0 |
| 66 | [Efficacy of intravitreal dexamethasone implant as a starting monotherapy and when switching from an anti-VEGF drug in diabetic macular edema]. 2021 , 137, 5-11 | | |
| 65 | Comparison of anatomical and functional outcomes of vitrectomy with internal limiting membrane peeling in recalcitrant diabetic macular edema with and without traction in Indian patients. <i>Indian Journal of Ophthalmology</i> , 2021 , 69, 3297-3301 | 1.6 | 0 |
| 64 | Factors Associated With the Presence of Foveal Bulge in Eyes With Resolved Diabetic Macular Edema. <i>Frontiers in Medicine</i> , 2021 , 8, 755609 | 4.9 | |
| 63 | Retinal non-perfusion in diabetic retinopathy. <i>Eye</i> , 2022 , | 4.4 | 3 |

| | | | |
|----|---|-----|---|
| 62 | Multifocal Electroretinogram Alterations after Intravitreal Ranibizumab Treatment in Diabetic Macular Edema.. <i>Beyoglu Eye Journal</i> , 2022 , 7, 39-46 | 0.1 | |
| 61 | History of Diabetic Eye Related Diseases. <i>Journal of Diabetes Mellitus</i> , 2021 , 11, 354-358 | 0.5 | |
| 60 | Estimation of the Level of Glycosylated Hemoglobin as a Predictor Factor to Bevacizumab Injection in Diabetic Macular Edema in a Sample of Iraqi Patients. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020 , 9, 1480-1483 | 1 | |
| 59 | Update on Current and Future Management for Diabetic Maculopathy.. <i>Ophthalmology and Therapy</i> , 2022 , 11, 489 | 5 | 0 |
| 58 | Current Management of Diabetic Macular Edema. | | 1 |
| 57 | KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema.. <i>American Journal of Ophthalmology</i> , 2022 , | 4.9 | 8 |
| 56 | Association between fluid volume in inner nuclear layer and visual acuity in diabetic macular edema.. <i>American Journal of Ophthalmology</i> , 2021 , | 4.9 | 1 |
| 55 | Transcytosis mechanisms of cell-penetrating peptides: Cation independent CC12 and cationic penetratin.. <i>Journal of Peptide Science</i> , 2022 , e3408 | 2.1 | |
| 54 | Fluocinolone acetonide implant in diabetic macular edema: International experts' panel consensus guidelines and treatment algorithm.. <i>European Journal of Ophthalmology</i> , 2022 , 11206721221080288 | 1.9 | 0 |
| 53 | Review of Studies Comparing Panretinal Photocoagulation and Anti-Vascular Endothelial Growth Factor Therapy in the Treatment of Proliferative Diabetic Retinopathy.. <i>Cureus</i> , 2022 , 14, e22471 | 1.2 | |
| 52 | Müller Glial Expression of REDD1 is Required for Retinal Neurodegeneration and Visual Dysfunction in Diabetic Mice.. <i>Diabetes</i> , 2022 , | 0.9 | 1 |
| 51 | Steroid Treatment in Macular Edema: A Bibliometric Study and Visualization Analysis.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 824790 | 5.6 | 1 |
| 50 | Diabetic retinopathy treatment and management during the COVID-19 pandemic. <i>Journal of Surgery and Medicine</i> , 2022 , 6, 336-341 | 0.1 | |
| 49 | Sources of bias in artificial intelligence that perpetuate healthcare disparities—A global review. 2022 , 1, e0000022 | | 3 |
| 48 | Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings.. <i>International Journal of Retina and Vitreous</i> , 2022 , 8, 23 | 2.9 | |
| 47 | Identifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic Macular Edema.. <i>International Journal of Molecular Sciences</i> , 2022 , 23, | 6.3 | 1 |
| 46 | Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DAM Study).. <i>Clinical Ophthalmology</i> , 2022 , 16, 1109-1115 | 2.5 | 0 |
| 45 | Intravitreal anti-vascular endothelial growth factor in diabetic macular oedema: scoping review of clinical practice guidelines recommendations.. <i>British Journal of Ophthalmology</i> , 2021 , | 5.5 | |

| | | | |
|----|--|-----|---|
| 44 | Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries.. <i>Ophthalmology and Therapy</i> , 2022 , | 5 | |
| 43 | Switching between anti-VEGF agents in the management of refractory diabetic macular edema: A systematic review.. <i>Survey of Ophthalmology</i> , 2022 , | 6.1 | 3 |
| 42 | Treat-and-Extend Versus Alternate Dosing Strategies with Anti-Vascular Endothelial Growth Factor agents to treat Center Involving Diabetic Macular Edema: A Systematic Review and Meta-analysis of 2346 Eyes.. <i>Survey of Ophthalmology</i> , 2022 , | 6.1 | 0 |
| 41 | Incidence, Risk Factors and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.. <i>Ophthalmology Retina</i> , 2022 , | 3.8 | |
| 40 | Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema. <i>Cells</i> , 2022 , 11, 1950 | 7.9 | 0 |
| 39 | Are intravitreal injections essential during the COVID-19 pandemic? Global preferred practice patterns and practical recommendations. <i>International Journal of Retina and Vitreous</i> , 2022 , 8, | 2.9 | 0 |
| 38 | Combination of vitrectomy and intentional macular detachment is associated with a faster edematous regression than vitrectomy alone in the treatment of refractory diabetic macular edema. <i>Retina</i> , 2022 , Publish Ahead of Print, | 3.6 | |
| 37 | The Use of Vascular Endothelial Growth Factor Inhibitors in Patients with Proliferative Diabetic Retinopathy. <i>Oftalmologiya</i> , 2022 , 19, 405-412 | 0.3 | |
| 36 | Anti-vascular endothelial growth factor therapy in diabetic macular edema: real-life outcomes from a multicenter study in Turkey over 36 months. <i>International Ophthalmology</i> , | 2.2 | |
| 35 | Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?. <i>Expert Opinion on Biological Therapy</i> , 1-17 | 5.4 | 0 |
| 34 | Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension. 2022 , 7, e001007 | | |
| 33 | Frequency and timing of antivasular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision: Protocol V results in context. 2022 , 7, e000983 | | |
| 32 | Expert Panel Consensus for Addressing Anti-VEGF Treatment Challenges of Diabetic Macular Edema in Spain. Volume 16, 3097-3106 | | 0 |
| 31 | Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review. 2022 , 22, 525-536 | | 0 |
| 30 | Optical Coherence Tomography Reflectivity in Foveal Cysts: A Novel Biomarker for Early-Response Prediction of Diabetic Macular Edema Treated with Dexamethasone. 2022 , 12, 1475 | | 0 |
| 29 | Deep learning to infer visual acuity from optical coherence tomography in diabetic macular edema. 9, | | 0 |
| 28 | Metformin therapy as a strategy to compensate anti-VEGF resistance in patients with diabetic macular edema. 2022 , 101, e31266 | | 0 |
| 27 | Direct Tie2 Agonists Stabilize Vasculature for the Treatment of Diabetic Macular Edema. 2022 , 11, 27 | | 1 |

| | | |
|----|---|---|
| 26 | Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review. Volume 16, 3503-3526 | 0 |
| 25 | Formal registration of visual impairment in people with diabetic retinopathy significantly underestimates the scale of the problem: a retrospective cohort study at a tertiary care eye hospital service in the UK. <i>bjophthalmol-2022-321910</i> | 0 |
| 24 | Long term outcomes following anti-VEGF therapy for diabetic macular edema. 1-13 | 0 |
| 23 | Stress response protein REDD1 promotes diabetes-induced retinal inflammation by sustaining canonical NF- κ B signaling. 2022 , 102638 | 0 |
| 22 | Diabetes mellitus associated neurovascular lesions in the retina and brain: A review. 2, | 0 |
| 21 | Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?. 126-133 | 1 |
| 20 | Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Effective?. 118-125 | 0 |
| 19 | Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials. | 0 |
| 18 | The intervention of epithelial-mesenchymal transition in homeostasis of human retinal pigment epithelial cells: a review. 1-13 | 0 |
| 17 | The Role of Angiopoietins in Neovascular Diabetes-Related Retinal Diseases. 2022 , 13, 1811-1821 | 1 |
| 16 | Evaluation of microaneurysms as predictors of therapeutic response to anti-VEGF therapy in patients with DME. 2022 , 17, e0277920 | 0 |
| 15 | Perspectives of diabetic retinopathy—challenges and opportunities. | 0 |
| 14 | Treatment results of diabetic macular edema with different choroidal thickness with intravitreal anti vascular endothelial growth factor. 2022 , 22, | 0 |
| 13 | Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial. 2022 , 9, | 1 |
| 12 | Endpoints of Anti-Vascular Endothelial Growth Factor Clinical Trials for Diabetic Macular Edema. 2022 , 185-198 | 0 |
| 11 | Intravitreal anti-vascular endothelial growth factor, laser photocoagulation, or combined therapy for diabetic macular edema: A systematic review and network meta-analysis. 14, | 0 |
| 10 | Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment. 2023 , | 0 |
| 9 | OCT outcomes as biomarkers for disease status, visual function, and prognosis in diabetic macular edema. 2023 , | 0 |

- 8 Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries. **2023**, 12, 809-826 ○
- 7 Benefit of intravitreal injections in patients with sub-threshold baseline visual acuity: a retrospective single-centre study. ○
- 6 Prospective, Observational, Multicenter, Real-World Study of the Efficacy, Safety, and Pattern of Use of the Dexamethasone Intravitreal Implant in Diabetic Macular Edema in France: Short-Term Outcomes of LOUVRE 3. ○
- 5 VEGF Induces Expression of Genes That Either Promote or Limit Relaxation of the Retinal Endothelial Barrier. **2023**, 24, 6402 ○
- 4 Introduction of Diabetic retinopathy and principles of treatment. **2024**, 1-26 ○
- 3 Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice. **2023**, 9, ○
- 2 Targeting angiogenesis in oncology, ophthalmology and beyond. ○
- 1 Global trends and performances in diabetic retinopathy studies: A bibliometric analysis. 11, ○